AstraZeneca Share Price, Forecast & Analysis (LON:AZN)

AstraZeneca trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

AstraZeneca announced a dividend on Thursday, July 25th. Stockholders of record on Thursday, August 8th will be given a dividend of GBX 71.90 per share on Monday, September 9th. This represents a dividend yield of 1.07%. The ex-dividend date of this dividend is Thursday, August 8th. The official announcement can be viewed at this link. View AstraZeneca's Dividend History.

AstraZeneca is scheduled to release their next quarterly earnings announcement on Friday, February 14th 2020. View Earnings Estimates for AstraZeneca.

17 Wall Street analysts have issued 12 month price targets for AstraZeneca's stock. Their forecasts range from GBX 5,500 to £100. On average, they expect AstraZeneca's stock price to reach GBX 7,465.67 in the next year. This suggests a possible upside of 3.0% from the stock's current price. View Analyst Price Targets for AstraZeneca.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 3 sell ratings, 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AstraZeneca.

Headlines about AZN stock have trended somewhat negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AstraZeneca earned a news impact score of -1.2 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for AstraZeneca.

Some companies that are related to AstraZeneca include GlaxoSmithKline (GSK), Bayer (BAYN), Dechra Pharmaceuticals (DPH), Hutchison China MediTech (HCM), Mayne Pharma Group (MYX), Opthea (OPT), Vectura Group (VEC), Medical Developments International (MVP), BEXIMCO PHARMAC/S GDR REGS (BXP), Eco Animal Health Group (EAH), Trilogy International Partners (TRL), Pharmaxis (PXS), Allergy Therapeutics (AGY), Futura Medical (FUM) and Vita Life Sciences (VLS).

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include GlaxoSmithKline (GSK), Hain Celestial Group (HAIN), Vodafone Group (VOD), National Retail Properties (NNN), NVIDIA (NVDA), BP (BP), Marks and Spencer Group (MKS), Royal Dutch Shell (RDSB), Encana (ECA) and Philip Morris International (PM).

Shares of AZN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

One share of AZN stock can currently be purchased for approximately GBX 7,248.

AstraZeneca has a market capitalization of £95.09 billion and generates £24.14 billion in revenue each year. AstraZeneca employs 64,400 workers across the globe.View Additional Information About AstraZeneca.

The official website for AstraZeneca is http://www.astrazeneca.com/.

AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, CAMBRIDGE, CB2 0AA, United Kingdom. The biopharmaceutical company can be reached via phone at +44-20-73045000.